ADIAL PHARMACEUTICALS, INC. ADIL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-43.14
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$8.0M | — | — | $5.3M |
| 2024 | — | -$13.2M | — | — | $4.1M |
| 2023 | — | -$5.1M | — | — | $4.1M |
| 2022 | — | -$12.7M | — | — | $3.3M |
| 2021 | — | -$19.4M | — | -$12.0M | $3.5M |
| 2020 | — | -$10.9M | — | — | $4.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Davidson Matt | Chief Development Officer | 2026-06-12 | Grant | 232,417 | — |
| Davidson Matt | Chief Development Officer | 2026-06-11 | Grant | 3,427 | — |
| Davidson Matt | Chief Development Officer | 2026-06-11 | Grant | 1,822 | — |
| Davidson Matt | Chief Development Officer | 2026-06-11 | Grant | 101 | — |
| Davidson Matt | Chief Development Officer | 2026-06-11 | Grant | 61,647 | — |
| Claiborne Cary J | Chief Executive Officer | 2026-04-07 | Grant | 37,985 | — |
| Goodman Tony | Chief Operating Officer | 2026-04-07 | Grant | 26,510 | — |
| Schuyler Kevin | director | 2026-04-07 | Grant | 9,185 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -43.14 (distress)
- Working capital / assets 0.717
- Retained earnings / assets -13.482
- EBIT / assets -1.169
- Equity / liabilities 3.777
Source: SEC EDGAR filings · CIK 0001513525 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.